Abstract
Chinese medicine is a national treasure that has been passed down for thousands of years in China. According to the statistics of the World Health Organization, there are currently four billion people in the world who use Chinese medicine to treat diseases, accounting for 80% of the world’s total population. However, the obscurity of its theory, its unmanageable quality, its complex compositions, and the unknown effective substances and mechanisms are great obstacles to the internationalization of Chinese medicine. Here, we propose a new strategy for the development of Chinese medicine: the clinical prescription (C)-protein (P)-small-molecule (S)-disease (D) strategy, namely the CPSD strategy. The strategy uses clinical prescriptions as the source of medicine and uses computer simulation technology to find small-molecule drugs targeting therapeutic proteins for treating specific diseases so as to deepen awareness of the value of Chinese medicine. At the same time, this article takes cardiovascular drug development as an example to introduce the application of CPSD, which will be instrumental in the further development, modernization, and internationalization of Chinese medicine.
Highlights
Chinese medicine, known as Chinese materia medica (CMM), is one of the major aspects of Traditional Chinese Medicine (TCM) (Xu et al, 2013)
For the criteria of selection of proteins or targets related to cardiovascular diseases, we investigated all of the literature related to cardiovascular disease pathways published between 2001 and 2018
CMM has been used for thousands of years in China and has enormous potential for drug development
Summary
Known as Chinese materia medica (CMM), is one of the major aspects of Traditional Chinese Medicine (TCM) (Xu et al, 2013). In addition to its downregulation, activating or up-regulating the JAK/STAT pathway was reported to prevent the oxidative stress-induced apoptosis of FIGURE 2 | Proteins or pathways associated with cardiovascular diseases. CAPEoNO2 can suppress oxidative stress by regulating the peroxisomal proliferators-activated receptor g-coactivator-1a (PGC-1a)/Nrf1/SOD1 pathway to protect heart function This protective effect is related to other pathways like Bcl-2 associated X Protein (Bax)/B-cell lymphoma-2 (Bcl-2) (Li et al, 2018b). Cycloastragenol, a natural compound with various pharmacological functions derived from Astragalus mongholicus Bunge (Huangqi), has been demonstrated to attenuate left ventricular dysfunction and cardiac remodeling in heart failure rat models (Wang et al, 2018b). (Shiliupi), was reported to exert cardioprotective effects by restricting oxidative stress and myocardial injury in a rat model of MI/R via activation of the AMPK signaling pathway (Ding et al, 2017). Natural small molecules for specific pharmacodynamic targets against cardiovascular diseases could be screened out conveniently, quickly, and successfully by using the CPSD strategy
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
